Skip to content
RARE·Nasdaq·US

Ultragenyx

Ultragenyx is a biopharmaceutical company that develops and commercializes therapies for serious rare and ultra-rare genetic diseases. Its portfolio includes approved therapies and product candidates across biologics, small molecules, AAV gene therapy, and nucleic acids. It commercializes products through its own commercial organizations and third-party distributors in North America, the EU, the U.K., Latin America, Türkiye, Asia, and select other markets.

Source: SEC 10-K Feb 18, 2026

Thematic Position

RARE

Relationship Groups

Suppliers1
Customers1
Partners4
Licensing6
Competitors5

Relationship details are part of the Pro plan.

Recent Discoveries

Recent discoveries are part of the Pro plan.

Ended Relationships

6 ended relationships · Ended relationships are part of the Pro plan.

Management Perspective on Regulatory & Geopolitical Developments

tariff
U.S. tariffs on pharmaceutical imports of up to 100% could raise Ultragenyx costs
SEC 10-QMay 6, 2026

The full regulatory passage is part of the Pro plan.

6 more · Regulatory and geopolitical insights are part of the Pro plan.

Disclosed customers above 10% of revenue

1 customer · Named major customers are part of the Pro plan.